23andMe Holding Co. ROA 2024

Hvad gør 23andMe Holding Co.?

23andMe Holding Co. is an American company for personalized genomics and health research. The company was founded in 2006 and is headquartered in Sunnyvale, California. The name of the company comes from the 23 chromosomes in the human genome and the English expression for "me". The main business of 23andMe is DNA analysis for consumers. Customers can send their DNA samples to the company, with tests being conducted on more than 30 genetic traits, uncovering disease risks, and creating family trees. 23andMe uses advanced sequencing technologies to analyze more than one million genetic variations in your genome. The DNA samples are tested based on single nucleotide polymorphisms (SNPs), which can provide information about disease risks, ethnic origins, and family health history. The results are then provided on an online platform where customers can view and share their DNA information. One unique aspect of 23andMe is that it also collects genetic information for research. 23andMe collaborates with various universities and research institutions to gather data for more complex studies. Customers can participate by anonymously sharing their genetic data for research purposes. 23andMe has many advantages, such as the ability to predict the risk of certain diseases. Based on your DNA, 23andMe can determine if there are altered genes in your body that are associated with specific diseases. However, the company emphasizes that this is not a diagnosis and should not replace medical advice. 23andMe also emphasizes that it supports customers in conversations with their doctors and gives them the opportunity to discuss the results with their doctors and relatives. In addition to DNA analysis, the company also offers a genetic report on your fitness traits. 23andMe also provides details on how to better understand your genetic information and what you can do to improve your health. In 2013, 23andMe underwent a regulatory investigation, which led to a significant restriction of its services. The company had to discontinue its health risk assessments for customers due to concerns from the FDA. The FDA was concerned that customers might make medical decisions based on 23andMe reports that may not necessarily be good for them. However, after many discussions with the FDA, the company decided to relaunch and is now an even more well-known and successful company. The company has more than 10 million customers worldwide and is continuously growing. An emotional incentive for consumers to use 23andMe is the desire to know where they come from and who their ancestors were. Nearly 50 percent of 23andMe customers have chosen to release their DNA information for research purposes. 23andMe has already contributed to various research initiatives that have made important contributions to genomics and precision medicine. Overall, 23andMe offers a unique experience for customers as it presents genomics and personal health data in an accessible way. It is also a significant contribution to research in the field. The company has achieved a lot despite regulatory challenges along the way. 23andMe Holding Co. ist eines der beliebtesten Unternehmen auf Eulerpool.com.